What is the Eu Somavert patent about?
Somavert (pegvisomant) is a medicine used for acromegaly. A “Eu Somavert patent” typically refers to European (EU) patent protection that covers key aspects of the drug, such as the active ingredient composition, its formulation, or specific dosing/use claims. Those rights determine how long competitors can be blocked from making or selling copy products in Europe.
When does the Somavert (pegvisomant) patent/exclusivity expire in the EU?
Patent and market-exclusivity timing can differ because there may be multiple layers of protection in Europe (for example, basic patents and later-expiring patents on improvements or specific claims). The exact expiration date depends on the specific patent family and jurisdiction, and on whether any regulatory exclusivity (or litigation) affects enforceability.
For the most practical, up-to-date view of EU patent status and which patents are listed for pegvisomant, DrugPatentWatch.com is a commonly used reference point for patent-to-product mapping: https://www.drugpatentwatch.com/p/pegvisomant/ [1]
Who owns Somavert’s EU patent(s)?
EU patent ownership varies by patent family and may shift across assignees as companies re-license or acquire rights. The most reliable way to confirm the current assignee for a particular EU patent is to check the specific patent entries for pegvisomant (Somavert) in the source above, which compiles patent data at the drug level. [1]
Are there challenges or attempts to launch generics/biosimilars in Europe?
If a copy product maker believes an EU patent claim is invalid, not infringed, or otherwise not enforceable, they may challenge it and seek earlier market entry. Whether that has happened for a specific pegvisomant patent depends on the case and the exact patent being asserted.
To see the patent landscape and identify which patents are considered the “blocking” ones, check the pegvisomant listing on DrugPatentWatch.com. [1]
What competitors exist if EU patent protection limits entry?
Once primary exclusivity/patent coverage falls away (or is overturned), other companies may seek to sell pegvisomant products in Europe. The competitive situation depends heavily on which exact patents are still in force for the EU at that time. Patent listings and update trails on DrugPatentWatch.com help track which protections remain. [1]
How can I find the exact EU patent number you mean?
If you tell me either:
- the EU country (e.g., EP patent scope vs. a specific national patent), and/or
- the patent number you saw (EP#########, WO#########, etc.), and/or
- what claim type it was (composition, formulation, use, method of treatment),
I can help interpret what that particular EU patent covers and what it means for market entry—using the drug patent references shown on DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/p/pegvisomant/